A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

  • Autism Spectrum Disorder
Trial Status:

Completed

This trial runs in
Cities
  • Austin
  • Bellevue
  • Cleveland
  • Dothan
  • Glasgow
  • Houston
  • Jacksonville
  • Minneapolis
  • New York
  • Orangeburg
  • Philadelphia
  • Phoenix
  • San Antonio
  • San Diego
  • Seattle
  • Stanford
  • Toronto
Trial Identifier:

NCT03611075 BP40331

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a non-drug study seeking to characterize different scales to measure repetitive and restrictive behaviors in different ASD sub-populations over time. This study will also explore the use of digital biomarkers.

      Hoffmann-La Roche Sponsor
      NCT03611075 , BP40331 , 2019-003524-20 Trial Identifier
      No Intervention Treatments
      Autism Spectrum Disorder Condition
      Official Title

      Study to Evaluate and Explore Scales for Repetitive and Restricted Behaviors and Digital Biomarkers in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

      Eligibility Criteria

      All Gender
      ≥ 5 Years & ≤ 45 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria

      Inclusion Criteria for All Participants

      • Males and females
      • Availability of a parent or other reliable caregiver. The same person must agree to accompany the participant to all clinic visits and provide information about the participant's behavior and symptoms

      Inclusion Criteria for Participants with Autism Spectrum Disorders (ASD)(Diagnostic evaluations will be completed at study site by research staff and supervised by a licensed psychologist)

      • Age: 5-45 years
      • Diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and the Autism Diagnostic Observation Schedule (ADOS-2).
      • Children's Yale-Brown Obsessive Compulsive Scale modified for ASD (CY-BOCS-ASD) total score of at least 12
      • Clinical Global Impression-Severity (CGI-S) scale of at least 4 about participant's current autism severity
      • Intelligence quotient (IQ) score of 50 or above as assessed by the Abbreviated Intelligence Quotient (ABIQ) SB5 scale
      • All medications and treatments are expected to be stable for the duration of the study

      Inclusion Criteria for Typically Developing (TD) Healthy Participants

        -TD participants aged 5-45 years
      Exclusion Criteria

      Exclusion Criteria for All Participants

      • Participation in an in investigational drug or device study within 4 weeks or 5 times the half-life of the investigational molecule prior to screening, and participant is not expected to enroll in any other trial during the study
      • Co-occurring disease, condition, or treatment that might interfere with the conduct of the study or pose an unacceptable risk to the participant
      • Unstable or uncontrolled clinically significant psychiatric and/or neurological disorder that may interfere with study objectives

      Exclusion Criteria for Participants with ASD -Known "syndromic" ASD (e.g. Fragile X syndrome, Angelman syndrome, Prader-Willi, Rett's syndrome, tuberous sclerosis, Dup15q syndrome) History of alcohol misuse and/or illicit drug use during the last 12 months of the study

      Exclusion Criteria for TD Healthy Participants

        -TD healthy participants with a first-degree relative with ASD

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now